Table 3.
Disease activity of RA evaluated by disease activity score for 28 joints at baseline and after 12 weeks of KBG treatment
| Week 0 | Week 12 | P-value | |
|---|---|---|---|
| T28 (0–28) | 3.6 ± 1.7 | 0.9 ± 0.3 | <0.05 |
| S28 (0–28) | 2.5 ± 0.8 | 1.2 ± 0.4 | <0.05 |
| GH (VAS; 0–100 mm) | 46.0 ± 5.6 | 41.3 ± 5.5 | NS |
| ESR (mm h−1) | 67.9 ± 9.9 | 71.1 ± 8.1 | NS |
| DAS28 | 4.7 ± 0.3 | 4.1 ± 0.3 | <0.05 |
Data represent mean ± SE (n = 14). T28, tender joint count (0–28); S28, swollen joint count (0–28); GH, patient's global assessment of disease activity (general health); VAS, visual analog scale; ESR, erythrocyte sedimentation rate; DAS28, disease activity score for 28 joints; NS, not significant.